SCHEMBL29344273

SCHEMBL29344273

NC(=O)Nc1c(F)cc(Cl)cc1C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.43
AKR1C4 P17516 2/20 0.41
AKR1C3 P42330 2/20 0.41
AKR1C2 P52895 2/20 0.41
AKR1C1 Q04828 2/20 0.41
ACLY P53396 3/20 0.40
DHODH Q02127 1/20 0.40
KEAP1 Q14145 1/20 0.39
NFE2L2 Q16236 1/20 0.39
GRIK1 P39086 2/20 0.38
HSD17B10 Q99714 2/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 2/20 0.38
TP53 P04637 1/20 0.38
NPC1 O15118 1/20 0.38
GRM2 Q14416 1/20 0.38
HPGD P15428 1/20 0.38
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
MAP2K1 Q02750 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3576620 0.83 KDM4E (0.53) CYP3A4AKR1C4AKR1C3AKR1C2AKR1C1
SCHEMBL29344133 0.83 KEAP1 (0.42) KEAP1NFE2L2HSD17B10KDM4EALDH1A1
SCHEMBL3584072 0.79 ALDH1A1 (0.43) CYP3A4AKR1C4AKR1C3AKR1C2AKR1C1
SCHEMBL15313171 0.74 ACLY (0.42) CYP3A4AKR1C4AKR1C3AKR1C2AKR1C1
SCHEMBL29918078 0.73 CYP3A4 (0.55) CYP3A4AKR1C4AKR1C3AKR1C2AKR1C1
SCHEMBL13469240 0.73 CYP3A4 (0.55) CYP3A4AKR1C4AKR1C3AKR1C2AKR1C1
SCHEMBL21381356 0.71 ACLY (0.42) ACLYDHODHALDH1A1TP53
SCHEMBL23529333 0.71 ALDH1A1 (0.48) CYP3A4AKR1C4AKR1C3AKR1C2AKR1C1
SCHEMBL6242355 0.71 AKR1C2 (0.64) CYP3A4AKR1C4AKR1C3AKR1C2AKR1C1
SCHEMBL374388 0.70 NPC1 (0.48) CYP3A4AKR1C4AKR1C3AKR1C2AKR1C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239788-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT TAIHO PHARMACEUTICAL CO., LTD. (JP) 2024-07-18 US disclosed
US-20240239788-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT TAIHO PHARMACEUTICAL CO., LTD. (JP) 2024-07-18 US disclosed
EP-4322954-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT Merck Sharp & Dohme LLC (US) 2024-02-21 EP disclosed
WO-2022221739-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT MERCK SHARP & DOHME CORP. (US) 2022-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239788-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT KRAS, NRAS, HRAS CYP3A4 4645/4885AKR1C4 4193/4885AKR1C3 3771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.